The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2025
Agitation in Alzheimer's Disease as a Qualifying Condition for Medical Cannabis in the United States: A Brief Report on Current Trends.
СтатьяResearch Support, N.I.H., IntramuralНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bonar Erin E, Tan Chiu Yi, Patyk Adam, Lei Lianlian, Maust Donovan T
Аннотация
OBJECTIVES: We assessed state-level access to medical cannabis with Alzheimer's Disease and related agitation (AD) as a qualifying condition.
METHODS: In 2024-2025, we examined regulatory agencies' publicly available online reports regarding medical cannabis, including use specifically for AD.
RESULTS: Of 38 states that allow medical cannabis, 19 (50%) allow medical cannabis for AD. AD accounts for <1% of medical cannabis certifications. Some data suggest that AD as a qualifying condition is declining in states that have legalized recreational cannabis use.
CONCLUSIONS: Despite limited evidence of efficacy supporting medical cannabis for AD, this remains a qualifying condition in 19 states, though it is invoked for a small minority of the population. With increasing medical and recreational cannabis access, there is a need for geriatric clinicians to assess and monitor cannabis use among the growing population of patients with AD across states with varied policies, particularly given decreases in medical program involvement.
METHODS: In 2024-2025, we examined regulatory agencies' publicly available online reports regarding medical cannabis, including use specifically for AD.
RESULTS: Of 38 states that allow medical cannabis, 19 (50%) allow medical cannabis for AD. AD accounts for <1% of medical cannabis certifications. Some data suggest that AD as a qualifying condition is declining in states that have legalized recreational cannabis use.
CONCLUSIONS: Despite limited evidence of efficacy supporting medical cannabis for AD, this remains a qualifying condition in 19 states, though it is invoked for a small minority of the population. With increasing medical and recreational cannabis access, there is a need for geriatric clinicians to assess and monitor cannabis use among the growing population of patients with AD across states with varied policies, particularly given decreases in medical program involvement.